Tianjin Tianyao Pharmaceuticals Co Ltd (600488) — Cash Flow-to-Debt Ratio
Tianjin Tianyao Pharmaceuticals Co Ltd (600488) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥13.19 Million could theoretically repay 0% of its total liabilities (CN¥1.85 Billion) in one year. See 600488 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tianjin Tianyao Pharmaceuticals Co Ltd Cash Flow-to-Debt Ratio (2000–2024)
Historical debt coverage capacity for Tianjin Tianyao Pharmaceuticals Co Ltd across 25 annual periods. For the full cash flow conversion analysis, see Tianjin Tianyao Pharmaceuticals Co Ltd (600488) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Tianjin Tianyao Pharmaceuticals Co Ltd (2000–2024)
Year-by-year debt coverage analysis for Tianjin Tianyao Pharmaceuticals Co Ltd. Check Tianjin Tianyao Pharmaceuticals Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.31x | CN¥569.37 Million | CN¥1.81 Billion | ▼ -4.1% |
| 2023 | 0.33x | CN¥783.01 Million | CN¥2.39 Billion | ▲ +45.3% |
| 2022 | 0.23x | CN¥653.52 Million | CN¥2.90 Billion | ▲ +80.0% |
| 2021 | 0.13x | CN¥316.89 Million | CN¥2.53 Billion | ▼ -13.2% |
| 2020 | 0.14x | CN¥346.88 Million | CN¥2.40 Billion | ▼ -12.4% |
| 2019 | 0.16x | CN¥279.37 Million | CN¥1.70 Billion | ▲ +32.2% |
| 2018 | 0.12x | CN¥189.27 Million | CN¥1.52 Billion | ▲ +1865.8% |
| 2017 | -0.01x | CN¥-8.15 Million | CN¥1.15 Billion | ▼ -105.7% |
| 2016 | 0.12x | CN¥63.32 Million | CN¥511.21 Million | ▼ -44.1% |
| 2015 | 0.22x | CN¥129.50 Million | CN¥584.42 Million | ▼ -37.9% |
| 2014 | 0.36x | CN¥178.76 Million | CN¥501.34 Million | ▲ +231.3% |
| 2013 | 0.11x | CN¥84.55 Million | CN¥785.64 Million | ▲ +489.2% |
| 2012 | 0.02x | CN¥13.23 Million | CN¥724.13 Million | ▼ -83.0% |
| 2011 | 0.11x | CN¥78.47 Million | CN¥729.86 Million | ▲ +18.6% |
| 2010 | 0.09x | CN¥116.82 Million | CN¥1.29 Billion | ▼ -77.8% |
| 2009 | 0.41x | CN¥435.13 Million | CN¥1.07 Billion | ▲ +98.5% |
| 2008 | 0.21x | CN¥219.31 Million | CN¥1.07 Billion | ▲ +8.1% |
| 2007 | 0.19x | CN¥162.33 Million | CN¥854.65 Million | ▲ +404.7% |
| 2006 | 0.04x | CN¥50.72 Million | CN¥1.35 Billion | ▲ +132.3% |
| 2005 | -0.12x | CN¥-108.87 Million | CN¥933.43 Million | ▼ -157.2% |
| 2004 | 0.20x | CN¥110.30 Million | CN¥541.10 Million | ▲ +198.1% |
| 2003 | 0.07x | CN¥45.77 Million | CN¥669.25 Million | ▼ -4.2% |
| 2002 | 0.07x | CN¥45.28 Million | CN¥634.50 Million | ▼ -58.4% |
| 2001 | 0.17x | CN¥71.87 Million | CN¥419.39 Million | ▲ +21.5% |
| 2000 | 0.14x | CN¥41.06 Million | CN¥291.03 Million | — |